Beyond Air (XAIR) reprices director options to $1.95

Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing.

Rhea-AI Filing Summary

Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing. On November 4, 2025, the board reduced the exercise price of certain outstanding stock options to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025.

The Form 4 shows multiple option awards previously carrying exercise prices of $10.80 and $5.892, each adjusted to $1.95. The company states that all other terms of the options remain unchanged. These options were granted under the Amended and Restated 2013 Equity Incentive Plan and continue to follow their existing vesting schedules, subject to the director’s continued service.

Insights

Equity compensation analyst

Form 4 records a board-approved option repricing to $1.95; terms unchanged.

The filing lists multiple director stock option awards whose exercise prices were reduced to $1.95 on November 4, 2025. Entries show prior strikes at $10.80 and $5.892, with adjustments recorded as paired disposals (D) of higher-strike options and acquisitions (A) of options at $1.95.

The company notes all other terms remain unchanged and options were issued under the Amended and Restated 2013 Equity Incentive Plan, continuing to vest per existing schedules, subject to service. This is an administrative equity compensation change; actual impact depends on future service and exercise decisions.

Insider Trade Summary

16 transactions reported

Mixed 16 txns

Insider Lucera Erick

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock Options (Right to buy)	2,250	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	2,250	$0.00	$0.00
Disposition	Stock Options (Right to buy)	2,000	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	2,000	$0.00	$0.00
Disposition	Stock Options (Right to buy)	1,500	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	1,500	$0.00	$0.00
Disposition	Stock Options (Right to buy)	1,250	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	1,250	$0.00	$0.00
Disposition	Stock Options (Right to buy)	1,250	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	1,250	$0.00	$0.00
Disposition	Stock Options (Right to buy)	1,000	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	1,000	$0.00	$0.00
Disposition	Stock Options (Right to buy)	1,250	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	1,250	$0.00	$0.00
Disposition	Stock Options (Right to buy)	3,750	$0.00	$0.00
Grant/Award	Stock Options (Right to buy)	3,750	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to buy) — 14,250 contracts (Direct)

Footnotes (2)

1. F1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.
2. F2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beyond Air (XAIR) report in this Form 4?

A board-approved repricing of certain director stock options to $1.95 per share effective November 4, 2025.

Which option exercise prices were changed for XAIR?

Options with prior strikes of $10.80 and $5.892 were adjusted to $1.95.

Did the repricing alter vesting terms for XAIR’s options?

No. The company states all other terms remain unchanged, including vesting schedules.

Under which plan were the XAIR options issued?

The options were issued under the Amended and Restated 2013 Equity Incentive Plan.

What date anchors the XAIR option repricing?

The repricing was effective on November 4, 2025, using the $1.95 close from November 3, 2025.

Who signed the Form 4 for Beyond Air?

The form was signed by /s/ Erick Lucera on 11/06/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 09:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucera Erick

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NY 11530

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,250	(2)	(2)	Common Stock	2,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,250		(2)	(2)	Common Stock	2,250	(1)	2,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,000	(2)	(2)	Common Stock	2,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,000		(2)	(2)	Common Stock	2,000	(1)	2,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,500	(2)	(2)	Common Stock	1,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,500		(2)	(2)	Common Stock	1,500	(1)	1,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,000	(2)	(2)	Common Stock	1,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,000		(2)	(2)	Common Stock	1,000	(1)	1,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$5.892	11/04/2025		D(1)			3,750	(2)	(2)	Common Stock	3,750	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		3,750		(2)	(2)	Common Stock	3,750	(1)	3,750	D

Explanation of Responses:

1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Erick Lucera	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.